Home
About Us
About Us
Board of Directors
Scientific Advisory Board
Management Team
Careers
For Researchers
Paxalisib
EVT801
Collaborating with Kazia
Publications and Presentations
For Partners
Our Current Partners
What We Are Looking For
For Patients
Accessing Kazia Drug Candidates in Clinical Trials
Accessing Kazia Drug Candidates for Compassionate Use
Resources for Patients
For Investors
Press Releases
ASX Announcements
Delisting from ASX
How to convert unlisted shares to ADSs
SEC Filings
Corporate Presentations
Annual Reports
Financial Reports
AGM
Corporate Governance
Shareholder Services
Media Centre
Overview
Video
Coverage
Contact
Contact Us
Subscribe to email alerts
Heading &
Sub-heading can be edited through HQI
Home
>
Media Centre
>
Coverage
Overview
Video
Coverage
Coverage
2-May-2024
Kazia reports successful stage 1 completion of the EVT801 Phase 1 clinical trial in advanced cancer patients
11-Feb-2024
Professor takes big step in fighting cancer which claimed his daughter
23-Dec-2023
Parents of kids with DIPG say funding for trial urgently needed
23-Nov-2023
Kazia provides overview of Paxalisib related presentations from the Society of Neuro-Oncology 2023 Annual Meeting
1-May-2023
Kazia Therapeutics appoints Dr John Friend as new CEO
4-Apr-2023
Kazia Therapeutics to present new pipeline molecule data at AACR 2023
6-Mar-2023
Kazia Therapeutics forms clinical collaboration for Australian Phase 2 study of paxalisib, targeting childhood cancers
28-Feb-2023
Kazia Therapeutics raises A$7 million to fund R&D pipeline
6-Feb-2023
After a successful $4.5 million cap raise and with cancer trial results to come, Kazia is optimistic for 2023
31-Jan-2023
ASX rose 6.2% in January: Aus shares closed the day 0.07% lower
Click here for archives
